Medical Devices DECODED
Previous edition: 07 May 2024
Share article
Get the full version straight to your inbox.
Exclusive access to our best-in-class data & intelligence
Subscribe now
Medtronic's renal denervation system receives approval in China
The Symplicity blood pressure procedure utilises radiofrequency energy to target overactive renal nerves linked to hypertension.
Medtronic has announced the approval of its Symplicity Spyral renal denervation (RDN) system by the National Medical Products Administration (NMPA) in China.
This marks a milestone as the first RDN system to receive such approval in the country.
The company is now set to navigate the provincial registration process, although it anticipates initially modest sales in China.
The latest development follows Medtronic’s approval from the US Food and Drug Administration (FDA) for the Symplicity Spyral system in November 2023, along with its launch in India and Canada.
The system also secured clearance under the Greater Bay Area policy in China, allowing commercial sales to hospitals within the region.
It is also known as the Symplicity blood pressure procedure, a minimally invasive technique that utilises radiofrequency energy to target overactive renal nerves linked to hypertension.
During the procedure, a catheter is inserted into the renal artery, where it delivers energy to the nerves, and is subsequently removed without leaving any implants.
Medtronic senior vice-president and cardiovascular portfolio coronary and renal denervation business president Jason Weidman said: “As the leader in renal denervation, we are looking forward to bringing the Symplicity blood pressure procedure to China, where high blood pressure rates continue to increase.
“As these rates continue to climb, the need for innovative, alternative treatments is strong. The Symplicity procedure can provide people in China with another potential option when seeking high blood pressure solutions, complementing lifestyle modifications and medication.”
The Symplicity Spyral system, tested in more than 25,000 patients worldwide, has demonstrated consistent blood pressure reductions with a mean decrease of 9mmHg at three months, 9.9mmHg at six months, and 18mmHg at three years, alongside very low rates of adverse events.
While it remains investigational in Japan, the system is approved for use commercially in more than 70 countries worldwide.
Latest news
GE HealthCare unveils SIGNA MAGNUS for advanced neuroscience
The SIGNA MAGNUS MR scanner is tailored for advanced imaging procedures in neurology, oncology, and psychiatry.
RapidAI's AngioFlow imaging solution gains FDA 510(k) clearance
The AngioFlow technology is designed to enhance clinical decision-making during neuro-interventional procedures.
FDA approves Geneoscopy's ColoSense test for CRC screening
The ColoSense test is to be used with the ColoSense Collection Kit, Test Kit, Software, and specific instruments.
Researchers hit ‘milestone' in light therapy for spinal cord injury study
The UK-based research team now hopes to develop a prototype for an implantable device.
KKR agrees to acquire Indian medical devices company Healthium
Healthium is engaged in developing, manufacturing and selling a broad range of surgical products worldwide.
Vesica Health rolls out new test for bladder cancer detection
The AssureMDx test aids in identifying patients at an increased risk for bladder cancer, allowing for timely urological referrals.
Elekta introduces AI-powered adaptive CT-Linac
The CT-Linac is designed to deliver both offline and online adaptive radiation therapy.
In our previous edition
Medical Devices Decoded
Angle signs AstraZeneca deal to develop prostate cancer assay
06 May 2024
Medical Devices Decoded
Karius secures $100m in Series C funding round
03 May 2024
Medical Devices Decoded
Medline agrees to acquire Ecolab's surgical solutions business for $950m
02 May 2024
Newsletters in other sectors
Aerospace, Defence & Security
Automotive
Medical Devices
Technology
Travel and Tourism
Search companies, themes, reports, as well as actionable data & insights spanning 22 global industries
Access more premium companies when you subscribe to Explorer